HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Results of treatment with topical mitomycin C 0.02% following excision of primary pterygium.

AbstractAIMS--The effectiveness of instillation of mitomycin C eyedrops on the recurrence rate of pterygium was assessed in patients undergoing primary pterygium surgery. Any side effects were also noted. METHODS--Primary pterygia in 38 consecutive patients were surgically excised during July to December 1992. After surgery, mitomycin C 0.02% eyedrops twice daily for 5 days as well as dexamethasone 0.1% four times tapered for the next 6 weeks were instilled. Postoperative follow up ranged from 6 to 11 months. RESULTS--In one patient the pterygium recurred after 3 months (recurrence rate 2.6%). The side effects encountered were: avascularised sclera in 13 cases between 1-10 months postoperatively; ocular discomfort and lacrimation in five cases; superficial punctate keratitis during the first month in three cases; pyogenic granuloma in two cases. In one patient steroid induced increased intraocular pressure was found 4 weeks after surgery. The adverse side effects were all mild, self limiting, and easily treated. CONCLUSION--This study suggests that postoperative instillation of mitomycin C 0.02% eyedrops twice daily for 5 days following excision of primary pterygium is an effective and safe treatment to obviate pterygium recurrence.
AuthorsR Rachmiel, H Leiba, S Levartovsky (Affiliation: Department of Ophthalmology, Kaplan Hospital, Rehovot, Israel.)
JournalThe British journal of ophthalmology (Br J Ophthalmol) Vol. 79 Issue 3 Pg. 233-6 (Mar 1995) ISSN: 0007-1161 [Print] ENGLAND
PMID7703200 (Publication Type: Journal Article)
Chemical References
  • Ophthalmic Solutions
  • Dexamethasone
  • Mitomycin
Topics
  • Administration, Topical
  • Adult
  • Aged
  • Dexamethasone (administration & dosage, therapeutic use)
  • Drug Therapy, Combination
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Mitomycin (administration & dosage, adverse effects, therapeutic use)
  • Ophthalmic Solutions
  • Prognosis
  • Prospective Studies
  • Pterygium (drug therapy, pathology, prevention & control, surgery)
  • Recurrence

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $45.00 USD